Press Release Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors Aug 18
Press Release Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results Aug 11